📰 Vertice Pharma News
Page 2 - Vertice Pharma News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Vertice Pharma. Real-time updates on events, politics, business and more.
November 22, 2021
Albuquerque, NM (PRWEB) November 22, 2021 -- Nob Hill Therapeutics (NHT) is pleased to announce the members of its Strategic Advisory Board. Under the
October 3, 2021
News and commentary from the endocrinology world
October 1, 2021
/PRNewswire/ -- Vertice Pharma announces the results of a recent study demonstrating the bioequivalence of Thyquidity™, an oral liquid solution of...
May 1, 2021
A new research study titled ” US Autoimmune Hemolytic Anemia Drugs market” successfully shows the entire scenario as well as a comprehensive overview
February 26, 2021
MannKind Corp. touted increased sales for its flagship drug Afrezza during its fourth quarter earnings report on Thursday, while pointing out its new direction toward therapies for lung and endocrine diseases. During the quarter, MannKind pulled in $10.1 million in revenue for Afrezza, its inhalable insulin, a 30 percent increase compared to sales in the same quarter of 2019. The Westlake Village biotech company reported an adjusted net loss of $13.2 million (-6 cents a share). That’s narrowe...
February 25, 2021
The autoimmune hemolytic anemia treatment Market research report thoroughly explains each and every aspect related to the Global autoimmune hemolytic anemia treatment Market, which facilitates the report’s reader to study and evaluate the upcoming market trend and execute the analytical data to promote the business. autoimmune hemolytic anemia treatment Market Insight: Global Autoimmune hemolytic anemia Treatment Market is growing at a steady CAGR in the forecast period of 2019-2026. Incre...
February 24, 2021
Vertice Pharma ("Vertice"), a specialty pharmaceuticals company focused on improving patients' health, today announced the launch of THYQUIDITY. THYQUIDITY is indicated as a replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism and as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer.*
December 16, 2020
Vertice Pharma Names Sandra Miceli Chief Financial Officer News provided by Share this article Share this article NEW PROVIDENCE, N.J., Dec. 16, 2020 /PRNewswire/ -- Vertice Pharma, a specialty pharmaceuticals company focused on improving patients health, today announced that Sandra Miceli will join the Company as Chief Financial Officer ("CFO"), reporting to Scott Meyers, Chief Executive Officer ("CEO"). Ms. Miceli brings over 25 years of experience in successful pharmaceutical growth compani...